Renaissance Technologies LLC Takes Position in GH Research PLC $GHRS

Renaissance Technologies LLC acquired a new stake in GH Research PLC (NASDAQ:GHRS) during the 1st quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund acquired 20,614 shares of the company’s stock, valued at approximately $290,000.

A number of other hedge funds have also recently made changes to their positions in the business. Barclays PLC grew its position in shares of GH Research by 63.4% during the fourth quarter. Barclays PLC now owns 2,118 shares of the company’s stock worth $27,000 after purchasing an additional 822 shares in the last quarter. North Star Investment Management Corp. purchased a new position in shares of GH Research in the first quarter worth $31,000. Mirae Asset Global Investments Co. Ltd. purchased a new position in shares of GH Research in the fourth quarter worth $38,000. Osaic Holdings Inc. boosted its position in shares of GH Research by 63.6% during the second quarter. Osaic Holdings Inc. now owns 6,175 shares of the company’s stock worth $75,000 after acquiring an additional 2,400 shares during the last quarter. Finally, JPMorgan Chase & Co. purchased a new position in GH Research during the second quarter valued at $79,000. Institutional investors own 56.90% of the company’s stock.

GH Research Price Performance

Shares of GHRS stock opened at $29.80 on Thursday. The company has a market cap of $2.04 billion, a PE ratio of -29.80 and a beta of 1.29. GH Research PLC has a 1 year low of $11.83 and a 1 year high of $31.44. The stock’s 50 day simple moving average is $26.83 and its two-hundred day simple moving average is $20.93.

GH Research (NASDAQ:GHRS) last announced its earnings results on Thursday, August 6th. The company reported ($0.23) EPS for the quarter, topping analysts’ consensus estimates of ($0.29) by $0.06. Equities research analysts expect that GH Research PLC will post -1.2 EPS for the current year.

Wall Street Analyst Weigh In

GHRS has been the topic of a number of research reports. HC Wainwright reiterated a “buy” rating on shares of GH Research in a report on Monday, August 10th. Cantor Fitzgerald raised their price objective on GH Research from $35.00 to $40.00 and gave the company an “overweight” rating in a research report on Friday, August 7th. Wells Fargo & Company began coverage on GH Research in a report on Monday, July 27th. They issued an “overweight” rating and a $44.00 target price on the stock. Citigroup reiterated an “outperform” rating on shares of GH Research in a research report on Friday, May 15th. Finally, Needham & Company LLC increased their price target on GH Research from $32.00 to $39.00 and gave the company a “buy” rating in a research note on Thursday, August 6th. Ten analysts have rated the stock with a Buy rating, one has given a Hold rating and one has given a Sell rating to the stock. According to data from MarketBeat.com, the stock presently has a consensus rating of “Moderate Buy” and a consensus price target of $45.00.

GH Research Company Profile

GH Research Holdings Inc is a clinical-stage biotechnology company dedicated to the development of novel treatments for neuropsychiatric disorders through the application of psychedelic-inspired compounds. Headquartered in Dublin, Ireland, the company focuses on harnessing the unique pharmacology of 5-methoxy-N-dimethyltryptamine (5-MeO-DMT) and related molecules to address high unmet medical needs in mental health.

The firm’s lead program, GH001, is an inhaled formulation of 5-MeO-DMT that has completed early-stage clinical trials assessing safety, tolerability and preliminary efficacy in treatment-resistant depression.